RECOVER/ARVIN-GOODS
Arvin Goods, the Seattle-based responsible apparel brand, has announced the release of its latest sock collection, crafted from Recover™ recycled cotton fiber. Since launching in 2019, the company has been at the forefront of sustainable fashion and is one of the few brands in the market utilizing recycled materials for its entire collection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215745837/en/
(Photo: Arvin Goods)
The latest launch features crew socks made from 79% recycled materials, including 43% recycled polyester and 36% Recover recycled cotton fiber. Recover’s proprietary recycled fiber is one of the lowest-impact fibers available in the market, significantly reducing the carbon and water footprint of the apparel supply chain. Manufacturing just one pair of Arvin Goods socks made with 36% Recover fiber saves up to 18 gallons of water compared to a pair made with conventional cotton.
Boris Mercier, SVP Marketing at Recover, said, “Our ongoing work with Arvin Goods was born out of a shared belief in the importance of circular fashion that never sacrifices quality, feel, or style. As the ingredient brand of reference in recycled cotton, we aim to educate consumers to make more conscious choices and accelerate the adoption of sustainable initiatives within the casual wear segment.”
For each pair of socks, responsibility is the core of Arvin’s approach to the design, manufacturing, and distribution. As well as using low-impact impact recycled materials, responsibility was also prioritized in the value chain. Thanks to Recover’s strategic partnership with Ferre Yarns, based locally in Alicante, Spain the impact of transportation was also minimized.
Dustin Winegardner, Managing Partner at Arvin Goods, commented, “We have been working with Recover™, and the Ferre family of yarns since the beginning of Arvin Goods. Making it official like this and stamping the R on our packaging is an exciting step for our brand. Being able to source materials in Spain, and manufacture nearby in Portugal moves us further in our mission to deliver The Cleanest Basics on the Planet.”
Paqui Ferre, Sales and Marketing Director at Ferre, also commented, “Ferre has been working with Arvin Goods since the beginning of its history. In a clear commitment to sustainability, Arvin makes products using our most iconic yarn, FBlue. Consistent with our brand vision, FBLUE 100% recycled yarns deliver the perfect combination of circularity, performance, and color accuracy. A blend with Recover recycled cotton that answers the global call for sustainably sourced yarns while providing inspiring colors for Arvin Goods products.”
The new collection not only exemplifies Arvin Goods' sustainable ethos but also provides customers with a stylish and comfortable choice for everyday wear. The brand continues to set a new standard for low-impact fashion, encouraging consumers to make conscious choices that positively impact the planet.
The Arvin Goods recycled fiber collection starts at $12 USD and is available to purchase through their website.
Find out more about the collaboration here.
About Arvin Goods
Established in 2019 Arvin Goods has set out to help clean up a dirty industry. By utilizing recycled base materials and minimizing the movement of materials in manufacturing they are reducing the impact of one of the world's most consumed categories. Basics.
Arvin Goods produces comfortable on-trend products, that also happen to be the lowest-impact socks in the marketplace. Arvin Goods is based in Seattle, Washington USA.
About Recover™
Recover™ is a leading materials science company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends at scale. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all. As a fourth-generation, family-owned company, and backed by recent investment from STORY3 Capital and Goldman Sachs, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
About Ferre
Ferre is a fourth-generation family business with a history of more than 75 years innovating the manufacture of high-quality recycled yarns. Our open-end spin factory is based in Banyeres de Mariola (Alicante), Spain and the company, founded in 1947, has been innovating the cotton recycled spinning process ever since.
We work every day to improve our products and help our customers to maximize the full potential of our low-impact yarns, always guided for the commitment of making more with less. Ferre yarns stand out for their quality and low-impact products, bringing accurate and beautiful colours to the sustainable fashion value chain.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215745837/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom